Nashville, TNNCT06398418Now EnrollingIRB Ready

Solid Tumor, Adult Clinical Trial in Nashville, TN

Access cutting-edge solid tumor, adult treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by Rise Therapeutics LLC

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access solid tumor, adult specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor, adult treatment provided free

Apply for This Nashville Location

Check if you qualify for this solid tumor, adult clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Solid Tumor, Adult Study in Nashville

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

Sponsor: Rise Therapeutics LLC

Who Can Participate

Inclusion Criteria

At least 18 years of age to 80
Ability to provide written informed consent
Unresectable stage III or stage IV melanoma, basal cell carcinoma, or squamous cell carcinoma as per the American Joint Committee on Cancer 2017 Guidelines (8th Edition) regardless of BRAF mutation status and other solid tumors.
Refractory to anti-PD (checkpoint Protein on Immune Cells called T cells)-1/L1 therapy per RECIST v1.1 defined as subject who has disease progression after receiving at least two complete cycles of ICI (immune checkpoint inhibitors) therapy or disease progression 6 months from initiation of ICI (immune checkpoint inhibitors) therapy while still on active therapy.
Life expectancy of greater than 3 months
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Subjects must have evaluable disease by CT (computer tomography) or MRI (magnet resonance imaging) per RECIST 1.1 criteria or clinically apparent disease that the investigator can follow for response.

Exclusion Criteria

Any serious medical condition or laboratory abnormality or psychiatric condition or any other significant or unstable concurrent medical illness (in the opinion of the Investigator) would preclude protocol adherence or would make the safety of the study drug difficult to assess
Treatment with systemic broad-spectrum antibiotics.
No active viral infections.
Coexisting severe chronic diseases other than cancer (autoimmunity, inflammatory diseases)
Secondary gastrointestinal motility disorders
History of solid organ transplant or bone marrow transplant
Prior CAR-T (chimeric antigen receptor) or allogeneic cellular therapy
Ongoing systemic immunosuppressive therapy, with the exclusion of prednisone (10 mg/day)
Concurrent therapy with any other investigational agent, vaccine, or device
Pregnant or breastfeeding or planning to conceive or father a child during the trial period
Subjects with untreated brain metastasis. Treated brain metastasis are permitted if stable
More than 4 prior systemic therapies
Other cancer medications during treatment period are not permitted
Enrollment in other clinical trials.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT06398418) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor, Adult Treatment Options in Nashville, TN

If you're searching for solid tumor, adult treatment options in Nashville, TN, this clinical trial (NCT06398418) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor, adult specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor, adult clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Nashville, TN

See all advanced solid tumors clinical trials recruiting in Nashville — not just this study.

Browse Advanced Solid Tumors Trials in Nashville →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN